Pharmaceutical Costs, Technology Innovation, Opportunities & Reality
March 10, 2009 By Girish Malhotra
ABSTRACT:
As long as companies are able to achieve the above objectives any inefficiencies in the product development, marketing, and manufacturing processes become irrelevant as the related costs are absorbed. Until recently, the priority has been to invent a new molecule, get it approved by regulatory authorities and get it to market. If profits are threatened, the development of additional and alternate markets is the first choice to regain revenue. With upcoming losses due to patent expirations, we are seeing the start of consolidation, acquisition, and relationships with biotech companies and with companies in the developing countries.
[READ THE FULL ARTICLE]